UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): October 6, 2021
____________________
Rapid Therapeutic Science Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
(State or other jurisdiction
of incorporation)
|
001-55018
(Commission File
Number)
|
46-2111820
(IRS Employer
Identification No.)
|
|
15800 Dooley Road, Suite 200
Addison, Texas
(Address of principal executive offices)
|
75001
(Zip code)
|
Registrant’s telephone number, including area code: (800) 497-6059
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
1
|
Item 7.01
|
Regulation FD Disclosure.
|
On October 6, 2021, Rapid Therapeutic Science Laboratories, Inc. (“Rapid Therapeutic”, “RTSL” or the “Company”) issued a press release disclosing that the Company’s Chief Executive Officer, Donal R. Schmidt, Jr., will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 - 14, 2021. Mr. Schmidt will deliver his corporate presentation on Tuesday, October 12, 2021, at 12:00 PM PT / 3:00 PM ET. Mr. Schmidt will also be available for one-on-one meetings throughout the conference.
Attached hereto as Exhibit 99.1 is a copy of the press release announcing the Company’s attendance at the conference.
A copy of the presentation which the Company will use at the conference is being furnished as Exhibit 99.2 to this Current Report on Form 8-K, and is also available on the Company’s website at www.rtslco.com which website includes information the Company does not desire to incorporate by reference into this report.
The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
|
Item 9.01
|
Financial Statements and Exhibits..
|
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1*
|
|
Press Release dated October 6, 2021
|
|
|
|
|
|
99.2*
|
|
Powerpoint Presentation
|
|
|
|
|
|
104
|
|
Inline XBRL for the cover page of this Current Report on Form 8-K
|
* Furnished herewith.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RAPID THERAPEUTIC SCIENCE
LABORATORIES, INC.
Date: October 12, 2021
/s/ Donal R. Schmidt, Jr.
Name: Donal R. Schmidt, Jr.
Title: Chief Executive Officer
3